Abstract
Flap endonuclease-I (FEN-1) is involved in DNA repair and considered to be a novel target for the development of anticancer agents. N-hydroxy urea derivatives have been reported as FEN-1 inhibitors. To derive in vitro and in silico correlation, we have performed 2D-quantitative structure activity relationship (QSAR) analysis and docking studies on these compounds. 2D-QSAR models were developed using multiple linear regression (MLR) analysis and cross-validation using leave one out (LOO) method. The best model displayed R2 of 0.806 and Q2 of 0.607. Docking study revealed key interactions with desired amino acids and compare well with the in vitro potency of the reported compounds. Both studies reveal a link between FEN-1 inhibition and physicochemical descriptors or interactions with amino acids in active site. The information generated is first of its kind and may be helpful in the design of novel FEN-1 inhibitors.
Keywords: Cancer, QSAR, docking, flap endonuclease-1, glide, FEN-1.
Current Computer-Aided Drug Design
Title:QSAR and Docking Studies of N-hydroxy Urea Derivatives as Flap Endonuclease-1 Inhibitors
Volume: 11 Issue: 4
Author(s): Pankaj Wadhwa, Priti Jain and Hemant R. Jadhav
Affiliation:
Keywords: Cancer, QSAR, docking, flap endonuclease-1, glide, FEN-1.
Abstract: Flap endonuclease-I (FEN-1) is involved in DNA repair and considered to be a novel target for the development of anticancer agents. N-hydroxy urea derivatives have been reported as FEN-1 inhibitors. To derive in vitro and in silico correlation, we have performed 2D-quantitative structure activity relationship (QSAR) analysis and docking studies on these compounds. 2D-QSAR models were developed using multiple linear regression (MLR) analysis and cross-validation using leave one out (LOO) method. The best model displayed R2 of 0.806 and Q2 of 0.607. Docking study revealed key interactions with desired amino acids and compare well with the in vitro potency of the reported compounds. Both studies reveal a link between FEN-1 inhibition and physicochemical descriptors or interactions with amino acids in active site. The information generated is first of its kind and may be helpful in the design of novel FEN-1 inhibitors.
Export Options
About this article
Cite this article as:
Wadhwa Pankaj, Jain Priti and Jadhav R. Hemant, QSAR and Docking Studies of N-hydroxy Urea Derivatives as Flap Endonuclease-1 Inhibitors, Current Computer-Aided Drug Design 2015; 11 (4) . https://dx.doi.org/10.2174/1573409912666151124233628
DOI https://dx.doi.org/10.2174/1573409912666151124233628 |
Print ISSN 1573-4099 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6697 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New 2-Oxopyridine/2-Thiopyridine Derivatives Tethered to a Benzotriazole with Cytotoxicity on MCF7 Cell Lines and with Antiviral Activities
Letters in Drug Design & Discovery A Pan-Cancer Review of <i>ALK</i> Mutations: Implications for Carcinogenesis and Therapy
Current Cancer Drug Targets Genetically Redirected T Lymphocytes for Adoptive Immunotherapy of Solid Tumors
Current Gene Therapy The Novel Multi-Target Iron Chelator, M30 Modulates HIF-1α-Related Glycolytic Genes and Insulin Signaling Pathway in the Frontal Cortex of APP/PS1 Alzheimer’s Disease Mice
Current Alzheimer Research Decreasing the Metastatic Potential in Cancers - Targeting the Heparan Sulfate Proteoglycans
Current Drug Targets Cancer Stem Cells: How can we Target them?
Current Medicinal Chemistry Improvement of malignant pleural mesothelioma immunotherapy by epigenetic modulators
Current Topics in Medicinal Chemistry Peptidic Tumor Targeting Agents: The Road from Phage Display Peptide Selections to Clinical Applications
Current Pharmaceutical Design Potentiation of Anti-Cancer Treatment by Modulators of Energy Metabolism
Current Pharmaceutical Biotechnology Drug Target Identification for Neuronal Apoptosis Through a Genome Scale Screening
Current Medicinal Chemistry Target Therapies in Pancreatic Carcinoma
Current Medicinal Chemistry Human Embryonic and Induced Pluripotent Stem Cell Based Toxicity Testing Models: Future Applications in New Drug Discovery
Current Medicinal Chemistry Apoptosis-Inducing Activity of the S100A8/A9 Heterodimer
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Natural Sirtuin Modulators in Drug Discovery: A Review (2010 -2020)
Current Medicinal Chemistry Lights and Shadows on Monoamine Oxidase Inhibition in Neuroprotective Pharmacological Therapies
Current Topics in Medicinal Chemistry Cross Talk between the Cardiovascular and Nervous Systems:Neurotrophic Effects of Vascular Endothelial Growth Factor (VEGF) and Angiogenic Effects of Nerve Growth Factor (NGF)-Implications in Drug Development
Current Pharmaceutical Design Tumor Protein p63/microRNA Network in Epithelial Cancer Cells
Current Genomics Targeting Schistosome Histone Modifying Enzymes for Drug Development
Current Pharmaceutical Design MicroRNAs in Cancer Therapy: From Bench to Bedside
Current Cancer Therapy Reviews